Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Behandlingsniveau og behandlingsstop ved benign lungesygdom

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Telemedicin til monitorering af inflammatoriske tarmsygdomme og colon irritabile

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Androgent insensitivitetssyndrom opdaget pga. diskordans mellem prænatale vurderinger af fosterkøn.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Behandling af tymom og thymuskarcinom

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Kønsmodificerende kirurgi i Danmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Osmotisk demyeliniseringssyndrom

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antibiotic treatment adequacy and death among patients with Pseudomonas aeruginosa airway infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acute Lung Injury in Critically Ill Patients: Actin-Scavenger Gelsolin Signals Prolonged Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Validation of the IPF-specific version of St. George's Respiratory Questionnaire

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.

Translated title of the contributionTreatment limitations or discontinuation in patients with benign pulmonary diseases
Original languageDanish
JournalUgeskrift for Laeger
Volume180
Issue number39
ISSN0041-5782
Publication statusPublished - 24 Sep 2018

ID: 56582120